Vertical: CNMBase Year: 2025
Market Size (2025)
$57.48M
Projected (2032)
$80.14M
CAGR (2022–2032)
4.9%
Key Players
8+
Market Overview
The Global Decoquinate Market was valued at USD 57.48 Million in 2025 and is projected to reach USD 80.14 Million by 2032, registering a CAGR of 4.86% during 2026–2032. The market expanded from USD 49.84 Million in 2022 to USD 54.81 Million in 2024, and is expected to add USD 22.66 Million in absolute value between 2025 and 2032.
Decoquinate is a synthetic 4-hydroxyquinolone anticoccidial administered in feed to prevent coccidiosis caused by Eimeria species in broiler chickens, cattle (including calves and veal calves), sheep and goats. It acts on the early asexual stages of the parasite and is used across preventive feeding programmes in poultry integrations, beef feedlots, dairy calf-rearing units and small ruminant operations. Demand is shaped by the economic burden of coccidiosis, the growth of commercial poultry and ruminant production, and the tightening of policy on antibiotic use in food-producing animals, under which chemical anticoccidials such as decoquinate remain authorised for preventive use in major markets.
Key Findings
Livestock: Cattle & Small Ruminants was the largest segment in 2025 with USD 31.62 Million (55.0% share), while Poultry is the fastest-growing segment with a CAGR of 5.61% over 2026–2032.
Physical Form: Premix dominated in 2025 with USD 48.86 Million (85.0% share) and is also the fastest-growing form with a CAGR of 4.99%.
Region: Asia Pacific was the leading region in 2025 with USD 24.14 Million (42.0% share), while Middle East & Africa is the fastest-growing region with a CAGR of 5.87%.
Country: China was the leading country in 2025 with USD 9.66 Million, while India is the fastest-growing country with a CAGR of 7.37% over 2026–2032.
Segmentation Summary
The market is segmented by livestock into Cattle & Small Ruminants and Poultry, and by physical form into Premix and Others. Cattle & Small Ruminants accounted for USD 31.62 Million in 2025, supported by the established use of decoquinate in calves, feedlot cattle, lambs and kids, while Poultry accounted for USD 25.87 Million and is expected to grow faster (CAGR 5.61% against 4.21%) on the back of expanding broiler output in Asia Pacific, Latin America and the Middle East & Africa. Premix, valued at USD 48.86 Million in 2025, is the standard commercial format for incorporation into compound feed; Others, valued at USD 8.62 Million, covers powder, granular and other presentations such as products for addition to milk or milk replacer.
Regionally, Asia Pacific accounted for USD 24.14 Million in 2025, led by China (USD 9.66 Million) and India (USD 4.35 Million). North America and Latin America each accounted for 18.0% of global value, at USD 10.35 Million and USD 10.35 Million respectively, but Latin America is projected to grow faster, at a CAGR of 5.21% compared with 3.92% for North America. Europe, valued at USD 8.62 Million in 2025, is the slowest-growing region with a CAGR of 3.44%, while the Middle East & Africa, the smallest region at USD 4.02 Million, is expected to record the highest CAGR of 5.87%.
Competitive Landscape Summary
The finished-product market is concentrated around the originator Deccox brand, which passed from Zoetis to Phibro Animal Health following the acquisition of Zoetis' medicated feed additive portfolio that closed on 31 October 2024. Huvepharma has entered with a generic decoquinate premix (Quinox) authorised in Europe in 2026. Active pharmaceutical ingredient (API) and premix supply is more fragmented, with a group of Chinese manufacturers including Jiangsu Lingyun Pharmaceutical, Jiangsu Sinopep-Allsino Biopharmaceutical, Zhejiang Share Bio-pharm, Changzhou ComWin Fine Chemicals and Farmasino serving feed premix producers and distributors worldwide.
Challenges and Opportunities
Key challenges include the risk of reduced parasite sensitivity under continuous use, competition from ionophores, other chemical anticoccidials and live coccidiosis vaccines, label restrictions that exclude laying hens and lactating dairy animals, and the cost of maintaining authorisations and residue data across jurisdictions. Opportunities arise from generic entry and portfolio consolidation, the rapid expansion of commercial poultry and feedlot production in emerging economies, and the fit of decoquinate within rotation and shuttle programmes and within production systems that restrict medically important antimicrobials.
Future Outlook
The market is expected to grow steadily through 2032, with value rising from USD 60.28 Million in 2026 to USD 80.14 Million in 2032. Growth will be led by Poultry and by Asia Pacific, Latin America and the Middle East & Africa, where commercial livestock production is expanding fastest, while North America and Europe are expected to record moderate, replacement-driven growth. Premix will remain the dominant form owing to its compatibility with feed-mill operations and medicated feed regulations.
Over the forecast period, the competitive environment is expected to be shaped by the integration of the Deccox portfolio into Phibro Animal Health, the gradual entry of generic decoquinate premixes in regulated markets, and continued price competition from Asian API and premix suppliers in emerging markets. Market participants that combine regulatory coverage, technical support for anticoccidial programme design and reliable API supply are expected to be best placed to benefit from rising livestock production and from the continued shift away from antibiotic growth promoters.
The Decoquinate Market market is projected to grow at a CAGR of 4.9% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Decoquinate (ethyl 6-decyloxy-7-ethoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate; CAS No. 18507-89-6; molecular formula C24H35NO5) is a synthetic quinolone-class anticoccidial agent. It is practically insoluble in water and is administered orally through feed. Decoquinate acts on the sporozoite and early schizont stages of Eimeria species and is used for the prevention of coccidiosis in broiler chickens, cattle, calves, sheep and goats. In the United States it is approved as a Type A medicated article for use in feed under 21 CFR 558.195, and in the European Union it is authorised as a coccidiostat feed additive for chickens for fattening under Regulation (EC) No 1831/2003, while premixes for cattle and sheep are authorised as veterinary medicinal products.
Included in the scope: revenues from decoquinate sold for animal use, including premixes and Type A medicated articles for incorporation into compound feed, and other forms such as powders, granular products and presentations for addition to milk or milk replacer, across cattle, small ruminant and poultry applications.
Excluded from the scope: other anticoccidials (ionophores such as monensin and salinomycin and other chemical anticoccidials such as toltrazuril, diclazuril and amprolium), coccidiosis vaccines, the value of the complete medicated feed into which decoquinate is incorporated, and non-veterinary uses such as research into human antiparasitic applications.
Research Objectives
To estimate the size of the global decoquinate market in value terms (USD Million) for the historic period 2022–2024 and the base year 2025, and to forecast it for 2026–2032.
To analyse the market by livestock (Cattle & Small Ruminants and Poultry) and by physical form (Premix and Others).
To assess the market across North America, Europe, Asia Pacific, Latin America and the Middle East & Africa, and across the key countries within each region.
To identify the drivers, restraints, opportunities, trends and challenges influencing demand for decoquinate in poultry and ruminant coccidiosis control.
To examine the regulatory frameworks governing decoquinate as a feed additive and veterinary medicinal product in major markets.
To evaluate the value chain from API synthesis and premix formulation to feed mills and livestock producers.
To profile the competitive environment, including the positioning of originator, generic and API suppliers and key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process combining secondary research, primary research and data triangulation. The process began with defining the market scope and segmentation, followed by the collection of information on livestock production, coccidiosis control practices, product approvals and supplier activity. Market estimates were developed using top-down and bottom-up approaches, validated through primary inputs, and projected over the forecast period using a factor-based forecasting model.
Secondary Research
Secondary research was used to build an understanding of the product, its regulatory status, livestock production trends and the supplier base. The principal source types were:
Government and regulatory bodies: the U.S. Food and Drug Administration (Center for Veterinary Medicine) and the Code of Federal Regulations, the Canadian Food Inspection Agency, the European Commission and the European Food Safety Authority, the European Medicines Agency, the UK Veterinary Medicines Directorate and Food Standards Agency, China's Ministry of Agriculture and Rural Affairs, Japan's Ministry of Health, Labour and Welfare and Ministry of Agriculture, Forestry and Fisheries, and Brazil's Ministry of Agriculture and Livestock.
Intergovernmental and statistical sources: FAO (FAOSTAT), the OECD-FAO Agricultural Outlook, USDA Foreign Agricultural Service and Economic Research Service publications, and the World Organisation for Animal Health.
Industry associations: national and regional feed manufacturers' associations, poultry and cattle producer associations, and animal health industry bodies.
Company sources: annual reports, investor presentations, regulatory filings and product literature of animal health companies, API manufacturers and premix producers.
Trade journals and scientific literature: poultry and livestock trade publications, veterinary parasitology journals and EFSA scientific opinions on coccidiostats.
Paid and trade databases: pharmaceutical ingredient sourcing databases, drug master file and product registration databases, and trade data.
Primary Research
Primary research was conducted to validate secondary findings, gather qualitative insights and refine market estimates. Interviews were carried out with participants on both the supply and demand sides of the market.
Supply side: executives and product managers at animal health companies, API manufacturers, premix producers and distributors, and regulatory affairs specialists.
Demand side: nutritionists and veterinarians at poultry integrators, feedlots and calf-rearing operations, feed mill managers, and livestock consultants.
The objectives of primary research were to validate the market size and segment splits, understand pricing and dosage practices, assess the adoption of decoquinate within anticoccidial programmes, and identify emerging trends, competitive dynamics and regional growth patterns.
Market Size Estimation
Top-down approach: the overall anticoccidial and medicated feed additive market was assessed and the share attributable to decoquinate was derived using information on product approvals, programme usage and supplier revenues, before being apportioned across livestock, physical forms, regions and countries.
Bottom-up approach: livestock populations and production volumes (broilers, calves, feedlot cattle, sheep and goats) were combined with estimates of the proportion of animals receiving decoquinate, typical inclusion rates and treatment durations, and average selling prices to estimate consumption and value at the country level, which was then aggregated to regional and global totals.
Data triangulation: estimates from both approaches were compared and reconciled with supplier-side information and primary research inputs to arrive at the final market figures.
Forecasting Methodology
The forecast was developed using a factor-based model. Factors considered included projected growth in poultry meat and beef production, livestock inventories, the prevalence and economic impact of coccidiosis, regulatory developments on antimicrobial use in food-producing animals, the adoption of coccidiosis vaccines and alternative products, pricing trends for API and premix, and macroeconomic indicators. Historic trends for 2022–2024 and the base year 2025 were used as the starting point, and each factor was assessed for its impact over the short, medium and long term.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Market values are expressed in nominal USD Million and are based on manufacturer-level selling prices.
Currency fluctuations are not separately modelled over the forecast period.
Existing regulatory authorisations for decoquinate in major markets are assumed to remain in force through 2032.
No major disruption to API supply or to global livestock trade beyond normal cyclical variation is assumed.
Limited public disclosure of product-level revenues by private manufacturers means certain estimates rely on triangulation and primary inputs.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global decoquinate market is moderately consolidated at the finished-product level and fragmented at the API level. The originator brand, Deccox, has historically accounted for the bulk of authorised finished products in North America, Europe and other regulated markets, and its ownership passed from Zoetis to Phibro Animal Health with the closing of Phibro's acquisition of the Zoetis medicated feed additive portfolio on 31 October 2024. Generic competition in regulated markets is at an early stage, with Huvepharma obtaining European authorisations for its Quinox decoquinate premix in 2026. In contrast, API and premix supply is fragmented, with several Chinese manufacturers producing decoquinate API and premixes for domestic use and for export to premix producers and distributors in Asia, Latin America, the Middle East and Africa.
Competition takes place on two levels. Among decoquinate suppliers, competition centres on regulatory approvals, product quality and consistency, pricing, technical support to nutritionists and veterinarians, and distribution reach. More broadly, decoquinate competes with ionophores, other chemical anticoccidials and coccidiosis vaccines for positions in poultry and ruminant health programmes, which places a premium on technical service and programme design support.
Key Player Positioning
Leaders: Phibro Animal Health Corporation is the leading participant following its acquisition of the Deccox portfolio. The company reported net sales of USD 1,518.1 Million for the fiscal year ended 30 June 2026 and has medicated feed additives as a core business. The acquired Zoetis portfolio included more than 37 product lines sold in approximately 80 countries and six manufacturing sites, giving Phibro the broadest decoquinate registration and distribution footprint, including Deccox and the granular Avi-Deccox 60G in the EU and Deccox premix for cattle and sheep in the U.K. and Ireland.
Challengers: Huvepharma, a privately owned, vertically integrated animal health company headquartered in Bulgaria with a broad anticoccidial portfolio, is the principal challenger in regulated markets following the authorisation of its generic decoquinate premix Quinox in the U.K. and EU member states in 2026. Zoetis, the world's largest animal health company with revenue of USD 9,467 Million in 2025, was the long-standing global holder of Deccox; following the divestiture its role in decoquinate is limited, but it retains significant industry experience and relationships with livestock producers.
Niche players: Chinese manufacturers including Jiangsu Lingyun Pharmaceutical, Jiangsu Sinopep-Allsino Biopharmaceutical, Zhejiang Share Bio-pharm, Changzhou ComWin Fine Chemicals and Farmasino supply decoquinate API and premixes. Their positioning is based on cost competitiveness, export orientation and supply to premix producers and distributors, particularly in Asia Pacific, Latin America and the Middle East & Africa.
Competitor Dashboard
The dashboard below rates each company on its decoquinate-related product portfolio, regional presence, strategic alliances and industry experience.
Threat of New Entrants: Low
Marketing authorisations, residue data and GMP requirements create significant regulatory barriers.
Established brand recognition of Deccox and integrator relationships favour incumbents.
Generic pathways exist, as shown by Huvepharma's authorisation in Europe, but require substantial dossier investment.
Bargaining Power of Suppliers: Medium
API production is concentrated in a limited number of manufacturers, mainly in China.
Multiple API sources with regulatory filings give product holders some ability to switch suppliers.
Chemical intermediates are widely available, limiting input-level supplier power.
Bargaining Power of Buyers: High
Large poultry integrators and feed mills purchase in volume and negotiate prices.
Buyers can switch between anticoccidial classes within rotation programmes.
Price sensitivity is high in emerging markets and commodity feed production.
Threat of Substitutes: High
Ionophores and other chemical anticoccidials are well-established alternatives.
Live coccidiosis vaccines are gaining adoption, particularly in antibiotic-free production.
Phytogenic and other natural products are positioned as partial alternatives.
Competitive Rivalry: Medium
The finished-product market is concentrated around a small number of authorised brands.
Competition intensifies with generic entry and lower-cost premixes from Asian manufacturers.
Competition among anticoccidial classes is stronger than competition among decoquinate suppliers.
Threat of New Entrants: Low.
Bargaining Power of Suppliers: Medium.
Bargaining Power of Buyers: High.
Threat of Substitutes: High.
Competitive Rivalry: Medium.
Market estimates by geography (2032)
InsightAsia Pacific leads with $34.92M by 2032, while Middle East & Africa is projected to grow fastest at a 5.8% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $9.21M | $11.16M | $13.53M | 3.9% | 17% |
| Europe | $7.75M | $9.22M | $10.92M | 3.5% | 14% |
| Asia Pacific | $20.56M | $26.87M | $34.92M | 5.4% | 44% |
| Latin America | $8.91M | $11.45M | $14.76M | 5.2% | 18% |
| Middle East & Africa | $3.41M | $4.51M | $6.00M | 5.8% | 7% |
| Total | $49.84M | $63.21M | $80.14M | 4.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$80.14M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cattle & Small Ruminants | $42.24M | 4.3% | 53% |
| Poultry | $37.90M | 5.6% | 47% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Decoquinate Market covering market dynamics, competitive landscape, and strategic outlook.
The Decoquinate Market market is projected to reach $80.14M by 2032, growing at 4.9% CAGR. The Cattle & Small Ruminants segment holds the largest share.
The decoquinate market is shaped by the economics of livestock production, the epidemiology of coccidiosis, the regulatory treatment of anticoccidials and antibiotics, and competition from alternative control methods. This chapter examines the macro and micro factors influencing the market, followed by the key drivers, restraints, opportunities, trends and challenges. The impact scores in the growth factor analysis below are analyst assessments, rated on a scale of 1 to 10, where a higher score indicates a stronger influence on the market during the period concerned.
High Economic Burden of Coccidiosis in Poultry and Ruminants
Coccidiosis remains one of the most economically significant diseases of intensively reared livestock. A widely cited study by Blake et al., published in Veterinary Research in 2020, estimated the global cost of coccidiosis in chickens at approximately GBP 10.4 billion per year at 2016 prices, equivalent to around GBP 0.16 per chicken produced, through mortality, reduced weight gain, poorer feed conversion and the cost of prevention and treatment. In cattle, sheep and goats, clinical and subclinical coccidiosis in young stock causes diarrhoea, weight loss and reduced performance, particularly under the stress of weaning, transport and confinement. Because Eimeria oocysts persist in litter and housing, producers rely on continuous preventive programmes rather than treatment after outbreaks. This preventive model sustains recurring demand for in-feed anticoccidials such as decoquinate, which is approved in major markets for broilers, calves, feedlot cattle, young sheep and young goats. The high cost of unmanaged coccidiosis relative to the per-animal cost of prevention ensures that anticoccidial use remains a standard element of commercial production economics.
Expansion of Poultry and Cattle Production
Global demand for animal protein continues to rise with population growth, urbanisation and higher incomes in emerging economies. The OECD-FAO Agricultural Outlook projects poultry to account for the largest share of growth in global meat production over the coming decade, reflecting its lower production cost, short production cycle and broad cultural acceptance. USDA Foreign Agricultural Service assessments point to continued expansion of chicken meat output in Brazil, China and the United States, while poultry production is scaling up rapidly in India, South-east Asia, Saudi Arabia and parts of Africa. In the ruminant sector, growth in feedlot finishing and in commercial dairy calf and lamb rearing increases the number of young animals raised in confined conditions where coccidiosis risk is highest. As production intensifies and integrators adopt standardised health programmes, the volume of medicated feed incorporating anticoccidials grows in line with animal numbers, supporting demand for decoquinate across both livestock segments.
Restrictions on Antibiotic Use in Food-Producing Animals
Regulatory and market pressure to reduce antibiotic use in livestock has reshaped animal health programmes. The European Union banned antibiotics as growth promoters from 1 January 2006 while keeping coccidiostats authorised as a separate feed additive category. China's Ministry of Agriculture and Rural Affairs withdrew growth-promoting antibiotic feed additives through Announcement No. 194, with feed production using them ending on 1 July 2020. In the United States, the Veterinary Feed Directive rules place medically important antimicrobials in feed under veterinary oversight, while decoquinate is not on the FDA list of drugs with VFD marketing status and remains available over the counter as a single ingredient. These measures have increased the importance of non-antibiotic tools for maintaining gut health and performance. Decoquinate, as a synthetic chemical anticoccidial rather than an antibacterial, can be used in many raised-without-antibiotics programmes that exclude ionophores, depending on the requirements of the certifying scheme, which supports its use in poultry production systems that restrict antibiotics.
Established Role in Ruminant Programmes and Rotation Strategies
Decoquinate has a broad set of ruminant indications that differentiates it from many poultry-focused anticoccidials. In the United States it is approved for cattle, including calves and veal calves, and for young sheep and young goats at 0.5 mg per kg of body weight per day for at least 28 days, and for combination use with monensin in confined beef cattle. In Canada, the Medicating Ingredient Brochure covers broilers, cattle, calves fed milk replacer and lambs fed in confinement, with a zero-day withdrawal period. In the United Kingdom, Deccox premix for sheep and cattle carries a claim to aid the prevention of abortion and perinatal losses due to toxoplasmosis in ewes. In poultry, decoquinate is used within shuttle and rotation programmes in which different anticoccidial classes are alternated to manage parasite sensitivity. Its zero-day withdrawal in broilers in the United States and Canada provides flexibility in finisher feeds. These attributes give decoquinate a durable position in calf, lamb and broiler health programmes.
Generic Entry and Portfolio Consolidation
The transfer of the Deccox portfolio to Phibro Animal Health in 2024, followed by the transfer of U.S. and EU regulatory holdings in 2025–2026, places decoquinate within a company whose core business is medicated feed additives. At the same time, the authorisation of Huvepharma's generic decoquinate premix in European markets in 2026 widens supply and can extend use into price-sensitive segments. Together, these developments create opportunities for broader market coverage and renewed commercial focus on the molecule.
Growth in Emerging Livestock Markets
Emerging economies in Asia Pacific, Latin America and the Middle East & Africa are expanding commercial poultry and cattle production and adopting structured animal health programmes. India is projected to record the highest CAGR among countries at 7.37% over 2026–2032, and Middle East & Africa is the fastest-growing region at 5.87%. Suppliers that build registration portfolios and distribution networks in these markets are positioned to capture above-average growth.
Formulation and Combination Product Development
Formulation improvements such as granular premixes (for example, Avi-Deccox 60G authorised in the EU alongside Deccox) improve flow, mixing homogeneity and dust control in feed mills. Approved combinations with other feed additives in the United States, and products for addition to milk or milk replacer for young calves, extend use into new feeding systems. Further development of convenient presentations for calf-rearing and small ruminant operations offers growth potential for the Others segment.
Risk of Reduced Parasite Sensitivity
Like other chemical anticoccidials, decoquinate can select for less sensitive Eimeria populations when used continuously in the same production system. Reduced field efficacy has historically limited the use of some quinolone anticoccidials as stand-alone products in broilers, and producers therefore restrict decoquinate to defined positions within rotation or shuttle programmes. The EU authorisation for chickens for fattening requires the authorisation holder to carry out post-market monitoring of Eimeria resistance. Concerns over sensitivity constrain the share of total anticoccidial use that any single chemical compound can capture and moderate volume growth.
Label Restrictions and Regulatory Cost
Decoquinate is not approved for laying hens or for lactating dairy animals producing milk for human consumption, which excludes large livestock populations from the addressable market. Maintaining authorisations requires periodic renewal, residue and safety data, and compliance with species-specific conditions such as the restriction on use with bentonite in U.S. feeds. In the EU, maximum carry-over limits for decoquinate in feed for non-target species add to manufacturing and feed-mill compliance requirements. These obligations raise costs for originators and generic entrants and can slow entry into smaller markets.
Competition from Alternative Coccidiosis Control Methods
Decoquinate competes with ionophores, which hold a large share of broiler anticoccidial programmes, with other chemical anticoccidials such as nicarbazin, diclazuril and toltrazuril, and with live coccidiosis vaccines that are increasingly used in broiler breeders, layers and in antibiotic-free broiler production. Phytogenic and other natural gut-health products are also positioned as alternatives. This competitive pressure limits pricing power and the share of programmes allocated to decoquinate.
Consolidation of Medicated Feed Additive Portfolios
Large animal health companies are reshaping portfolios, with some divesting medicated feed additives to focus on vaccines, biologics and companion animal products, and specialists acquiring them. The Zoetis–Phibro transaction is the clearest example in this market and is shifting decoquinate stewardship to a feed-additive specialist.
Shift towards Antibiotic-Free and Vaccine-Based Programmes
The growth of antibiotic-free poultry production is changing anticoccidial programme design. While this favours chemical anticoccidials over ionophores in some systems, it also accelerates adoption of live vaccines, creating a mixed effect on decoquinate demand.
Dependence on Concentrated API Supply
Decoquinate API production is concentrated among a limited number of manufacturers, many located in China. This creates exposure to supply interruptions, environmental compliance actions and export logistics, and encourages buyers to qualify multiple sources and maintain safety stock.
Feed Mill Compliance and Dosing Accuracy
Effective use of decoquinate depends on accurate inclusion and homogeneous mixing, adherence to species restrictions and avoidance of cross-contamination of feeds for non-target animals. Regulations such as the EU carry-over limits and Canada's Feeds Regulations, 2024, which introduce preventive control and traceability requirements, increase the compliance burden on feed manufacturers.
The decoquinate value chain extends from chemical intermediates to livestock producers. Each stage is described below.
Raw materials and inputs: decoquinate is produced by multi-step organic synthesis. The key intermediate, 4-decyloxy-3-ethoxyaniline, is prepared from substituted nitrobenzene precursors through alkylation and reduction, and is condensed with diethyl ethoxymethylenemalonate before thermal cyclisation to form the quinolone ring. Inputs include fine chemical intermediates, solvents and high-temperature heat-transfer media, together with carriers such as calcium carbonate or cereal-based materials used in premix formulation.
API manufacturing: synthesis, purification and drying of the active ingredient under GMP conditions, with control of related substances and particle size. API production is concentrated among specialised manufacturers, many in China, supplying both originator and generic product holders.
Premix and product formulation: the API is blended with carriers to produce standardised premixes (for example, 6% Type A medicated articles or 60.6 g/kg premixes) and other forms such as granular products and powders for milk or milk replacer. Product holders maintain the marketing authorisations and residue data.
Distribution and channels: products reach the market through direct sales to integrated poultry companies and large feed mills, through animal health distributors and feed additive traders, and through veterinary channels where products are prescription-only, such as the POM-V classification in the United Kingdom.
Feed manufacturing: commercial and on-farm feed mills incorporate the premix into complete feeds, supplements or milk replacers at the approved inclusion rate.
End users: broiler integrators and growers, beef feedlots, dairy calf and veal rearing operations, and sheep and goat producers, advised by nutritionists and veterinarians.
April 2024: Phibro Animal Health Corporation; Acquisition; Entered into a definitive agreement to acquire the medicated feed additive product portfolio of Zoetis, including the Deccox decoquinate brand, for USD 350 million.
April 2024: Zoetis Inc.; Divestiture; Agreed to divest its medicated feed additive portfolio, including decoquinate products, to Phibro Animal Health as part of a focus on vaccines, biologics and other innovative livestock products.
October 2024: Phibro Animal Health Corporation; Acquisition; Completed the acquisition of the Zoetis medicated feed additive portfolio on 31 October 2024, adding more than 37 product lines sold in approximately 80 countries and six manufacturing sites.
July 2025: Phibro Animal Health Corporation; Regulatory Transfer; Commission Implementing Regulation (EU) 2025/1419 named Phibro Animal Health SA as the holder of the EU authorisation for decoquinate (Deccox and Avi-Deccox 60G) for chickens for fattening.
April 2026: Phibro Animal Health Corporation; Regulatory Transfer; The U.S. FDA published the change of sponsor for Deccox new animal drug applications, including combination approvals, from Zoetis to Phibro Animal Health.
May 2026: Huvepharma; Product Approval; Received U.K. authorisation from the Veterinary Medicines Directorate for Quinox 60.6 mg/g premix for medicated feeding stuff for cattle and sheep, a generic decoquinate product.
July 2026: Huvepharma; Product Approval; Received authorisation for Quinox decoquinate premix for cattle and sheep in Cyprus, extending its European registration footprint.
Political
Government policies to reduce antibiotic use in livestock, such as the EU growth-promoter ban and China's Announcement No. 194, shape anticoccidial programme design.
Food security and self-sufficiency programmes in countries such as Saudi Arabia and India support the expansion of domestic poultry production.
Trade policies and tariffs affect the cross-border movement of API and premixes, particularly from China.
Economic
Feed grain prices influence producer margins and spending on feed additives.
Rising incomes in emerging economies increase demand for poultry meat and beef.
Price competition from generic premixes and Asian API suppliers affects market value.
Social
Consumer demand for antibiotic-free meat influences the choice of anticoccidials in poultry.
Growing awareness of animal welfare supports preventive disease control in young stock.
Urbanisation and dietary change increase consumption of processed poultry products.
Technological
Granular premix formulations improve mixing homogeneity and reduce dust in feed mills.
Advances in coccidiosis vaccines and diagnostics influence programme design.
Precision feeding and feed-mill automation improve dosing accuracy.
Environmental
Environmental compliance requirements for chemical API plants affect supply continuity.
Oocyst persistence in litter and housing requires continuous preventive programmes.
Climate-related heat and humidity conditions influence coccidiosis pressure in tropical regions.
Legal
Marketing authorisations, maximum residue limits and withdrawal periods define permitted use.
Feed manufacturing regulations, including carry-over limits and preventive controls, govern medicated feed production.
Periodic re-authorisation requirements, such as the EU ten-year authorisation cycle, require updated safety and efficacy data.
Profiles of 27 companies operating in the Decoquinate Market market, including revenue, employee count, and market positioning where available.
Showing 27 of 27 companies
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix | Revenue type | Characterisation | Evidence | |---|---|---| | Product sales | Dominant (estimated well above 90% of revenue; exact split not publicly disclosed) | Manufactured coatings, sealants, admixtures and similar products sold through retail, distribution and direct channels | | Installation and services | Material within CPG and PCG; not separately disclosed | WTI/WTC roofing services, turnkey general contracting, TremCare maintenance programs, Stonhard installed flooring, Legend Brands/RoofTec restoration services, Pure Air Control Services | | Warranty and extended programs | Embedded in pricing; generates deferred revenue | Current unearned revenue USD 75.3M and long-term unearned revenue USD 92.4M at FY2026 (standardized balance sheet) | | Licensing and royalties | Minor | The 10-K notes license fees and royalty income from numerous international license agreements, plus equity-method joint ventures | | Subscription | None identified | — | RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Customer types and end markets | End market | Segment exposure | Representative brands | |---|---|---| | Commercial / institutional building envelope (roofing, walls, waterproofing, sealants) | CPG | Tremco, Dryvit, Nudura, illbruck, Kalzip, Volteco | | Concrete, cement and infrastructure | CPG, PCG | Euclid, Toxement, Viapol, Prime Resins, Fibrecrete | | Industrial maintenance, oil and gas, petrochemical, power, data centres | PCG | Carboline, Stonhard, Fibergrate, Nullifire | | Food and pharma | PCG | Mantrose-Haeuser, NatureSeal, Profile Food Ingredients | | Marine, wood finishes, powder coatings | PCG | Pettit, Woolsey, FinishWorks/Mohawk, TCI | | Residential DIY and professional painters | Consumer | Rust-Oleum, Zinsser, Varathane, DAP | | Household cleaning | Consumer | The Pink Stuff, Krud Kutter, Mean Green | | Pigments, colorants, OEM and personal care | Consumer (Color Group) | Day-Glo | | Restoration services equipment | CPG (Legend Brands) | Dri-Eaz, Sapphire Scientific | ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
3 interactive charts drawn from the Decoquinate Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Decoquinate Market By Physical Form
Global Decoquinate Market By Livestock
Global Decoquinate Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
